Td Asset Management Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Td Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$20.26 - $31.91 $3.42 Million - $5.38 Million	168,697 Added 82.92%	372,146 $8.12 Million
Q2 2023 Aug 09, 2023	BUY	$23.9 - $35.38 $531,201 - $786,355	22,226 Added 12.26%	203,449 $6.47 Million
Q1 2023 May 10, 2023	SELL	$22.82 - $35.32 $98,605 - $152,617	-4,321 Reduced 2.33%	181,223 $4.42 Million
Q3 2022 Nov 07, 2022	BUY	$25.5 - $41.42 $64,668 - $105,041	2,536 Added 1.39%	185,544 $5.17 Million
Q2 2022 Aug 04, 2022	SELL	$20.62 - $37.15 $263,936 - $475,520	-12,800 Reduced 6.54%	183,008 $4.84 Million
Q1 2022 May 10, 2022	SELL	$23.5 - $35.38 $477,050 - $718,214	-20,300 Reduced 9.39%	195,808 $6.86 Million
Q4 2021 Feb 10, 2022	BUY	$29.21 - $44.64 $1.22 Million - $1.86 Million	41,632 Added 23.86%	216,108 $7.01 Million
Q3 2021 Nov 09, 2021	BUY	$21.26 - $38.85 $422,776 - $772,571	19,886 Added 12.86%	174,476 $5.15 Million
Q2 2021 Aug 11, 2021	BUY	$12.56 - $29.69 $500,830 - $1.18 Million	39,875 Added 34.76%	154,590 $3.81 Million
Q1 2021 May 14, 2021	BUY	$12.37 - $17.74 $959,380 - $1.38 Million	77,557 Added 208.72%	114,715 $1.58 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $364,891 - $678,876	37,158 New	37,158 $616,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.